Literature DB >> 33636170

The bile acid TUDCA and neurodegenerative disorders: An overview.

Lucas Zangerolamo1, Jean F Vettorazzi2, Lucas R O Rosa1, Everardo M Carneiro1, Helena C L Barbosa3.   

Abstract

Bear bile has been used in Traditional Chinese Medicine for thousands of years due to its therapeutic potential and clinical applications. The tauroursodeoxycholic acid (TUDCA), one of the acids found in bear bile, is a hydrophilic bile acid and naturally produced in the liver by conjugation of taurine to ursodeoxycholic acid (UDCA). Several studies have shown that TUDCA has neuroprotective action in several models of neurodegenerative disorders (ND), including Alzheimer's disease, Parkinson's disease, and Huntington's disease, based on its potent ability to inhibit apoptosis, attenuate oxidative stress, and reduce endoplasmic reticulum stress in different experimental models of these illnesses. Our research extends the knowledge of the bile acid TUDCA actions in ND and the mechanisms and pathways involved in its cytoprotective effects on the brain, providing a novel perspective and opportunities for treatment of these diseases.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Bile acids; Huntington's disease; Neurodegeneration; Neuroprotection; Parkinson's disease

Mesh:

Substances:

Year:  2021        PMID: 33636170     DOI: 10.1016/j.lfs.2021.119252

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: Effects on cell apoptosis, oxidative stress and inflammation in the brain.

Authors:  Fei Huang
Journal:  Brain Behav Immun Health       Date:  2021-09-21

2.  Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets.

Authors:  Min Song; Fenglin Zhang; Yiming Fu; Xin Yi; Shengchun Feng; Zhichang Liu; Dun Deng; Qiang Yang; Miao Yu; Canjun Zhu; Xiaotong Zhu; Lina Wang; Ping Gao; Gang Shu; Xianyong Ma; Qingyan Jiang; Songbo Wang
Journal:  J Anim Sci Biotechnol       Date:  2022-06-08

3.  Alleviation of Endoplasmic Reticulum Stress Enhances Human Corneal Epithelial Cell Viability under Hyperosmotic Conditions.

Authors:  Damien Guindolet; Ashley M Woodward; Eric E Gabison; Pablo Argüeso
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

4.  Energy homeostasis deregulation is attenuated by TUDCA treatment in streptozotocin-induced Alzheimer's disease mice model.

Authors:  Lucas Zangerolamo; Carina Solon; Gabriela M Soares; Daiane F Engel; Licio A Velloso; Antonio C Boschero; Everardo M Carneiro; Helena Cristina L Barbosa
Journal:  Sci Rep       Date:  2021-09-13       Impact factor: 4.379

Review 5.  Targeting Microglia to Treat Degenerative Eye Diseases.

Authors:  Sean K Wang; Constance L Cepko
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

6.  Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts.

Authors:  Jasmine A Fels; Jalia Dash; Kent Leslie; Giovanni Manfredi; Hibiki Kawamata
Journal:  Ann Clin Transl Neurol       Date:  2022-09-09       Impact factor: 5.430

7.  Bile Acids Gate Dopamine Transporter Mediated Currents.

Authors:  Tiziana Romanazzi; Daniele Zanella; Mary Hongying Cheng; Behrgen Smith; Angela M Carter; Aurelio Galli; Ivet Bahar; Elena Bossi
Journal:  Front Chem       Date:  2021-12-10       Impact factor: 5.221

Review 8.  Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease.

Authors:  Agata Mulak
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 9.  Physiological Role of Bile Acids Modified by the Gut Microbiome.

Authors:  Yoshimitsu Kiriyama; Hiromi Nochi
Journal:  Microorganisms       Date:  2021-12-30

Review 10.  Mitochondrially-Targeted Therapeutic Strategies for Alzheimer's Disease.

Authors:  Isaac G Onyango; James P Bennett; Gorazd B Stokin
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.